Palliative & End-of-Life Distress
Palliative and end-of-life distress represents a significant psychosocial challenge faced by patients with life-limiting illnesses, significantly impacting quality of life. Recent research suggests that psychedelic compounds, particularly psilocybin, may offer promising therapeutic benefits in alleviating existential distress and improving psychological well-being in these patients.
Key Insights
- 1
Psilocybin-assisted therapy has shown potential in reducing existential distress in terminal cancer patients, with studies indicating significant improvements in psychological well-being.
- 2
Recent trials highlight that psilocybin can facilitate meaningful therapeutic experiences, leading to lasting positive changes even after a single session.
- 3
The acceptability of psilocybin treatment appears to be high among patients and healthcare professionals, suggesting a readiness to embrace psychedelic therapies in palliative care settings.
What is Palliative & End-of-Life Distress?
Palliative and end-of-life distress often manifest as psychological turmoil experienced by patients undergoing advanced illnesses, typically characterised by anxiety, depression, and existential fear concerning death.
The pathophysiology involves complex interactions between psychological well-being, neurobiology, and the stress of facing mortality, leading to profound emotional distress.
Common symptoms include severe anxiety about death, pervasive sadness, feelings of helplessness, and an overall decline in quality of life, often necessitating psychological intervention.
Current Treatments
Standard treatments often include psychotherapy, pharmacological interventions (such as antidepressants and anxiolytics), and palliative care practices aimed at managing symptoms rather than curing the illness.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Palliative & End-of-Life Distress.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Multiple studies support its significant effect on reducing end-of-life distress in patients. | Large | High | Consistent |
| LSD Some studies report benefits for anxiety and depression, but results are less conclusive than those for psilocybin. | Medium | Moderate | Inconsistent |
| MDMA Research shows potential for MDMA in treating anxiety and distress, but further studies are needed. | Medium | Moderate | Inconsistent |
| Ketamine Demonstrates rapid antidepressant effects, providing symptomatic relief in terminal illness settings. | Medium | Moderate | Consistent |
Psilocybin and Palliative & End-of-Life Distress
Psilocybin is believed to facilitate profound psychological experiences that can offer insights and a sense of peace in terminally ill patients. Research indicates that it can significantly alleviate anxiety and existential distress, leading to an enhanced emotional state and a greater acceptance of mortality. Many patients report transformative experiences that contribute to their overall well-being and comfort during palliative care.
Ketamine and Palliative & End-of-Life Distress
Ketamine acts as an NMDA receptor antagonist, offering rapid relief from depressive symptoms, which can be particularly distressing for patients facing end-of-life issues. Its psychedelic properties, combined with its fast-acting nature, make it a candidate for palliative care to improve mood and reduce anxiety, potentially improving patients' overall quality of life.
Clinical Outlook
The integration of psychedelics such as psilocybin into palliative care represents a frontier in treating end-of-life distress, promising enhanced quality of life for patients facing terminal illnesses. Continued research and clinical trials are imperative to establish safety, efficacy, and appropriate therapeutic protocols.
Industrial Landscape
Key industry players include academic research institutions and non-profits such as MAPS (Multidisciplinary Association for Psychedelic Studies) and the Heffter Research Institute, which support psychedelic research and advocate for the therapeutic use of psychedelics in healthcare.
Quick Indicators
Related Topics
Organisations
Search →OPEN Foundation
Dutch nonprofit organizer in the psychedelic field, including stewardship of the ICPR conference series and related professional convenings.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
MAPS
Nonprofit organizer and host of the Psychedelic Science conference series, alongside broader educational and policy programming.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Ketamine Research Institute
The Ketamine Research Institute is a US-based clinical research organization developing precision medicine approaches to ketamine infusion therapy, studying optimized dosing protocols to treat depression and offering clinician training in evidence-based ketamine practice.
University of California, San Francisco
University of California, San Francisco (UCSF) hosts major psychedelic research activity through the Translational Psychedelic Research Program (TrPR), Neuroscape Psychedelics Division, and psychiatry-led clinical research on psychedelic-assisted therapies.
University of Washington
At UW, researchers are working on clinical trials with psilocybin (provided by Usona). Dr Anthony Back, co-director of the University's Center for Excellence in Palliative Care, led a trial exploring the effects of psilocybin to alleviate the mental health burden inflicted on frontline healthcare workers throughout the COVID-19 pandemic. As Seattle became the largest city in the US to decriminalise psilocybin mushrooms in October 2021, and with ongoing legislative efforts at the state level, more research with psychedelics is anticipated and occurring at UW.
Vancouver Island University
In response to the fallout from the COVID-19 pandemic, a research group at Vancouver Island University (VIU) has been awarded funding from the Canadian Institutes of Health Research for the exploration of psychedelic therapies for front-line workers. Led by Dr Shannon Dames, the team are currently focusing on ketamine-assisted therapy for front-line workers experiencing symptoms of PTSD and emotional distress as a result of their experiences working through the pandemic.
University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
University of Zurich
Within the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
University of Auckland
The University of Auckland hosts academic psychedelic research activity, including work led by Professor Suresh Muthukumaraswamy on LSD microdosing and related mental health applications.
Usona Institute
Usona Institute is a US-based 501(c)(3) non-profit medical research organisation (MRO) headquartered in Madison, Wisconsin. Co-founded in 2014 by Bill Linton (CEO of Promega Corporation) and Malynn Utzinger, M.D., Usona was established after Linton witnessed the profound impact of a Johns Hopkins psilocybin study on a terminally ill friend. Unlike commercial drug developers, Usona operates as a mission-driven MRO — conducting and supporting pre-clinical and clinical research on psilocybin and other consciousness-expanding medicines, with the goal of developing accessible, affordable treatments. Its research leadership includes Dr. Charles Raison (Director of Clinical and Translational Research, UW-Madison psychiatrist) and Dr. Alexander Sherwood (medicinal chemist). Usona's psilocybin programme received FDA Breakthrough Therapy Designation for major depressive disorder in 2019. After completing the Phase 2 PSIL201 study (the largest Phase 2 randomised controlled trial of psilocybin for MDD at the time), the Institute launched the Phase 3 uAspire trial in 2024 — a 240-participant, randomised, double-blind, multicentre study comparing 25 mg psilocybin vs placebo in adults with MDD. Usona is also exploring 5-MeO-DMT in early-stage research.
People
Search →Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Joost Breeksema
Postdoctoral researcher and Executive Director of the OPEN Foundation
He is a prominent psychedelic researcher and advocate whose work helps shape evidence-based psychedelic policy, ethics, and patient-centered understanding of psychedelic and ketamine/esketamine treatments.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Michiel Van Elk
Associate Professor of Cognitive Psychology at Leiden University
Michiel van Elk is a prominent psychedelic science researcher known for rigorous, skeptical work on psilocybin, microdosing, expectancy effects, and the psychological mechanisms and risks of psychedelic experiences.
Jolien Veraart
Psychiatrist and PhD researcher at the University Medical Center Groningen / University of Groningen
She is a leading clinical researcher on ketamine and oral esketamine for treatment-resistant depression, including safety, efficacy, and real-world implementation.
Philippe Lucas
Director, Research and Safe Access at MAPS
He is a prominent Canadian psychedelic and cannabis researcher whose work has helped establish early evidence on ayahuasca-assisted therapy, psychedelic survey research, and harm-reduction policy.
Frederick Sundram
Associate Professor and Deputy Head of the Department of Psychological Medicine at the University of Auckland
He is a psychiatrist and clinical researcher contributing to psychedelic and novel-antidepressant studies, including LSD microdosing and ketamine/depression research.
Yvan Beaussant
Instructor in Medicine at Harvard Medical School and palliative care physician at Dana-Farber Cancer Institute
He is a leading clinical researcher in psychedelic-assisted therapy for serious illness, especially cancer-related depression, demoralization, and existential distress.
Neşe Devenot
Senior Lecturer in the University Writing Program at Johns Hopkins University
Neşe Devenot is a notable critic and scholar of psychedelic medicine whose work examines ethics, public discourse, and the social meanings of psychedelic-assisted therapy.
Christopher Davoli
Associate Professor of Psychology at Central Michigan University
He is a cognitive psychologist whose work with colleagues has helped document acute and longer-term effects of psychedelics on perception, experience, and psychological outcomes.
Heith Copes
Professor of Criminal Justice at the University of Alabama at Birmingham
Heith Copes is a criminologist whose research connects drug use, identity, and narrative meaning, including multiple collaborations on classic psychedelics, microdosing, and related social/behavioral outcomes.
Connected Evidence
The latest clinical data and verified academic findings associated with Palliative & End-of-Life Distress.